期刊文献+

低剂量替吉奥一线治疗高龄晚期胃癌的临床观察 被引量:1

Clinical observation of low-dose S-1 in the first-line treatment of elderly patients with advanced gastric cancer
暂未订购
导出
摘要 目的观察低剂量替吉奥一线治疗高龄晚期胃癌的疗效及安全性。方法治疗组36例高龄晚期胃癌患者给予低剂量替吉奥口服化疗,对照组32例给予最佳支持治疗,3个周期后评价疗效,并观察不良反应。结果治疗组和对照组的客观有效率分别为22.2%和3.1%,疾病控制率分别为58.3%和32.3%,两组差异均有显著性(P<0.05)。治疗组不良反应主要为血液学毒性、消化道反应和疲乏等,但较轻微。结论低剂量替吉奥口服治疗高龄晚期胃癌疗效较好,不良反应较轻,患者耐受性较好。 Objective To observe the efficacy and safety of low-dose S-1 in the first-line treatment of elderly patients with advanced gastric cancer.Methods The therapy group included 36 elderly patients was treated with low-dose S-1 orally.The control group included 32 cases was treated with best supportive care.The efficacy and adverse reaction were evaluated after 3 cycles of chemotherapy.Results The objective response rates (RR) of the therapy group and the control group were 22.2% and 3.1%.The disease control rates (DCR) were 58.3% and 32.3%.There were significant differences between two groups (P0.05).The adverse reactions in the therapy group were mild,including hematological toxicity,digestive tract reaction and fatigue.Conclusion Low-dose S-1 orally had good efficacy,mild adverse reactions and favorable tolerability in the treatment of elderly patients with advanced gastric cancer.
出处 《中国老年保健医学》 2012年第6期49-50,53,共3页 Chinese Journal of Geriatric Care
关键词 替吉奥 低剂量 高龄 晚期胃癌 S-1 low dose elderly advanced gastric cancer
  • 相关文献

参考文献11

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61(2): 69-90.
  • 2Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evalua- tion criteria in solid tumours : revised RECIST guideline ( version 1.1 ) [J]. Eur J Cancer, 2009, 45(2): 228 -247.
  • 3Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggre- gate data [ J ]. J Clin Oncol, 2006, 24 (18) : 2903 - 2909.
  • 4Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group [ J ]. J Clin Oneol, 2006, 24 (31): 4991 - 4997.
  • 5Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer [J]. N Engl J Med, 2008, 358 (1) : 36 -46.
  • 6Dank M, Zaluski J, Barone C, et al. Randomized phase Ⅲ study com- paring irinotecan combined with 5 - fluorouracil and folinic acid to cis- platin combined with 5 - fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junc- tion [J]. Ann Oncol, 2008, 19(8) : 1450-1457.
  • 7Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5 -fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase Ⅲ noninferiority trial [ J]. Ann Oncol, 2009, 20 (4) : 666 - 673.
  • 8Shirasaka T. Development history and concept of an oral anticancer a- gent S - 1 ( TS - 1 ) : its clinical usefulness and future vistas [ J ]. Jpn J Clin Oncol, 2009, 39( 1 ) : 2 -- 15.
  • 9Koizumi W, Narahara H, Hara T, et al. S - 1 plus cisplatin versus S - 1 alone for first-line treatment of advanced gastric cancer ( SPIRITS trial) : a phase Ⅲ trial [J]. Lancet Oncol, 2008, 9(3) : 215 -221.
  • 10Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combi- nation of irinotecan plus cisplatin versus S - 1 in metastatic gastric cancer: a randomised phase 3 study [ J]. Lancet Oncol, 2009, 10 (11) : 1063 -1069.

同被引文献14

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部